The complete guide to advertising higher risk non-surgical cosmetic procedures in Australia (2026)

The cosmetic sector built its marketing on exactly the material this guideline restricts. Before-and-after grids, patient stories, influencer partnerships and aspirational lifestyle imagery were not peripheral to how clinics grew — they were the growth engine. A guideline that removes them does not trim the edges of a marketing strategy; it removes the strategy.

That is why the remediation problem is usually larger than it first appears. A clinic with a decade of posting is not dealing with a handful of non-compliant items. It is dealing with an archive built on a model that is no longer permitted, across two regulators, where the historic content still counts. Ahpra has operated a Cosmetic Surgery Enforcement Unit with a dedicated advertising compliance team since September 2022, and had proactively audited the advertising of more than 120 doctors and clinics by April 2024. Advertising complaints assessed across all regulated health services rose from 380 in 2022/23 to 775 in 2024/25.

The guideline defines these as non-surgical procedures undertaken to revise appearance, where the dominant purpose is achieving a more desirable appearance and which usually require the involvement of a registered health practitioner. They may involve prescription-only medicines, injection of products into the skin, or penetration of the skin by chemicals, light, lasers, heat or cold.

Named examples: cosmetic injectables including botulinum toxin and dermal fillers, dental veneers, injection lipolysis, thread lifts, sclerotherapy, platelet-rich plasma procedures, and hair transplants.

Critically, the guideline binds registered practitioners, individuals who are not registered, and businesses, partnerships and corporate entities. A clinic's corporate social account is an advertiser in its own right. The obligation attaches to the procedure being advertised, not to whether the account holder personally holds registration.

Section 3.1 states that advertising of higher risk cosmetic procedures must not use testimonials, given their potential to create unrealistic expectations. A testimonial is any positive statement about the experience of, reason for, or outcome of a procedure, or about a practitioner's skills or experience, whether direct or comparative (s.3.2–3.3).

The scope surprises most clinics. Under s.3.4 the prohibition reaches print, websites, social media, in-clinic display and time-restricted formats such as stories. Under s.3.5 a practitioner is considered to have used a testimonial where they link to testimonials in third-party advertising, re-share patient posts that are recommendations or positive statements, or interact with reviews on third-party sites — including liking or responding to them.

Section 3.6 gives the practical answer: a practitioner is not responsible for what patients post independently, but must take steps to avoid interacting with it, and may reduce risk by disabling reviews, comments or tagging. Section 3.7 preserves patients' own freedom to share their experiences; the restriction is on the advertiser, not the public.

This is where the guideline most clearly departs from the December 2020 rules, which permit before-and-after imagery subject to a warning. Here, s.5.4 sets five conditions and they are cumulative:

• s.5.4.1 — both images genuine, actual patients, procedure performed by the advertising practitioner
• s.5.4.2 — the most prominent or first image must be the composite or the before image
• s.5.4.3 — images as similar as possible in content, lighting including flash, camera angle, background, framing, exposure, posture, clothing and makeup
• s.5.4.4 — no editing or enhancement: no filters, retouching or grey-scaling
• s.5.4.5 — timing considered, specifying how long after the procedure the after image was taken

Section 5.3 separately requires a prominent warning on outcome imagery that results are relevant only to that patient. The warning discharges s.5.3 alone. It does not rescue an image that fails any part of s.5.4, and it does not make a patient statement permissible. The practical consequence is that the standard remediation instinct — add a disclaimer and keep the post — produces content that is still non-compliant.

Related restrictions sit in s.5.2 (no models or celebrities not established to have had the procedure; no airbrushing or soft filtering), s.5.5 (no images of people under 18), s.5.6 (no entertainment framing — music, dancing, comedic comment, montage editing), and s.5.7 (no sexualised or lifestyle imagery, no emoji emotional reactions, no captions such as "perfect", "instant" or "ideal", no naming patients or linking to their accounts).

Section 6 requires accurate, realistic and educative information about risks. Section 6.3 is the one breached most often by omission: full risk information must be easily found within the advertising. The public should not have to search exhaustively or contact the practitioner, and for limited-space formats such as social media the advertising must direct people to the risk information by link or website direction.

Minimising terms — "gentle", "simple", "safe", "quick", "easy" — must not be used without clear risk information (s.6.2). Procedures must not be offered as competition prizes (s.6.4). Recovery time and pain must be realistic and not downplayed (s.6.5–6.6).

Sections 7 and 8 govern how outcomes and bodies may be described. Advertising must not imply natural ageing or normal variation is abnormal or undesirable (s.7.3.1), must not suggest procedures restore self-esteem or that someone is unattractive without them (s.7.3.2), must not promote "youthful", "ideal" or "flawless" imagery (s.7.3.4), and must not use phrases such as "happier you" or "best version of yourself" (s.7.3.5). Outcome claims must be objective and demonstrable, with "perfect pout" given as an unacceptable example (s.8.1.1), and must not mislead as to how quickly an effect appears, how long it lasts, or how often it must be repeated (s.8.2).

Two obligations are easy to fix and frequently missed: s.2.7 requires advertising that references a specific individual performing procedures to include that practitioner's registration details and registration number, and s.2.8 excludes trivialising titles such as "doll-maker", "magic hands", "sculptor" or "world's best".

Botulinum toxin products are Schedule 4 prescription-only medicines. Advertising a prescription-only medicine to the general public is prohibited under the Therapeutic Goods Act 1989, and no part of the Ahpra guideline changes that. Naming "Botox", "Dysport" or "Xeomin" in public-facing content — including price lists, hashtags and page titles — is a separate breach before a separate regulator.

The TGA requested removal of over 13,700 unlawful advertisements from digital platforms in 2024–25, and therapeutic goods used in cosmetic procedures is one of its stated compliance priority focus areas from 1 January 2026. Maximum civil penalties reach $15.65 million for corporations and $1.565 million for individuals.

CompliGUARD assesses cosmetic advertising against the Ahpra higher risk non-surgical cosmetic procedures guidelines, the December 2020 Ahpra Advertising Guidelines, the Therapeutic Goods Advertising Code 2021 and Australian Consumer Law in a single pass, extracting each claim from copy and imagery and returning a low, medium or high risk assessment with the specific clause behind every finding. Practitioner advertising breaches and prescription-only product breaches are reported under separate headings, because they are separate obligations before separate regulators requiring separate remediation — and where content cannot be made compliant by rewriting, the assessment says so rather than proposing a disclaimer. Every review is retained as an audit trail.

CompliGUARD provides compliance and creative marketing insights based on TGA, FSANZ, ACCC and AHPRA guidance as current at the time of review. The Therapeutic Goods Advertising Code is currently under formal review by the TGA (2025–26). CompliGUARD assessments reflect the current Code; guidance may be subject to change. This output does not constitute legal advice.

• Publishing without checking the complete advertisement’s overall impression.
• Treating one regulator’s checklist as coverage for every applicable framework.
• Failing to retain evidence showing what was reviewed and approved before publication.

CompliGUARD reviews the complete advertisement against TGA · AHPRA · FSANZ · ACCC requirements, identifies clause-level risks, proposes compliant wording, and retains the result in an audit trail before publication.